Pharmacogenomics for neurohormonal intervention in heart failure.
McNamara
Dennis M
DM
University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA. mcnamaradm@upmc.edu
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D004341:Drug Evaluation; D006333:Heart Failure / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists; D018377:Neurotransmitter Agents / Q000235:genetics*; D052250:Nitric Oxide Synthase Type III / Q000187:drug effects / Q000235:genetics; D007703:Peptidyl-Dipeptidase A / Q000235:genetics; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D011943:Receptors, Adrenergic, beta / Q000145:classification / Q000187:drug effects / Q000235:genetics; D018570:Risk Assessment / Q000379:methods
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000451:Mineralocorticoid Receptor Antagonists; D018377:Neurotransmitter Agents; D011943:Receptors, Adrenergic, beta; D052250:Nitric Oxide Synthase Type III; D007703:Peptidyl-Dipeptidase A